These findings overall indicate that MTC-22 is an easy-to-handle ovarian clear cell carcinoma cell line that could be used to investigate the pathophysiology of ovarian clear cell carcinoma, particularly cases marked by PIK3CB mutations, and to develop and validate new therapeutic modalities for this malignancy. Here, PIK3CB is linked to ovarian clear cell cancer.